Abstract
Hepatitis C is a current pandemic liver disease caused by the hepatitis C virus (HCV) with high morbidity and mortality. Recently, the direct-acting antiviral agents (DAAs) targeting HCV NS3/4A, NS5A and NS5B have become the most effective therapies against HCV infection in the clinical treatment. Among them, the second-generation of NS3/4A inhibitors have emerged as the mainstay of the DAA therapies, which are derived from the peptide substrate of NS3/4A protease and modified with various tailor-made amino acids in order to achieve high sustained virologic response (SVR) against HCV. This review summarizes sixteen examples of the second-generation of HCV NS3/4A inhibitors, mainly focusing on the clinical application, structure development, structure-activity relationship (SAR) and their synthesis.
Keywords: Hepatitis C virus (HCV), pandemic, direct-acting antiviral agents (DAAs), NS3/4A protease inhibitor, tailor-made amino acids, structure-activity relationship (SAR), asymmetric synthesis, ring-closing metathesis (RCM).
Current Pharmaceutical Design
Title:The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity
Volume: 23 Issue: 30
Author(s): Shuni Wang, Yibing Wang, Jiang Wang, Tatsunori Sato, Kunisuke Izawa*, Vadim A. Soloshonok*Hong Liu*
Affiliation:
- Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka 533-0024,Japan
- IKERBASQUE, Basque Foundation for Science, Alameda Urquijo 36-5, Plaza Bizkaia, 48011 Bilbao,Spain
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203,China
Keywords: Hepatitis C virus (HCV), pandemic, direct-acting antiviral agents (DAAs), NS3/4A protease inhibitor, tailor-made amino acids, structure-activity relationship (SAR), asymmetric synthesis, ring-closing metathesis (RCM).
Abstract: Hepatitis C is a current pandemic liver disease caused by the hepatitis C virus (HCV) with high morbidity and mortality. Recently, the direct-acting antiviral agents (DAAs) targeting HCV NS3/4A, NS5A and NS5B have become the most effective therapies against HCV infection in the clinical treatment. Among them, the second-generation of NS3/4A inhibitors have emerged as the mainstay of the DAA therapies, which are derived from the peptide substrate of NS3/4A protease and modified with various tailor-made amino acids in order to achieve high sustained virologic response (SVR) against HCV. This review summarizes sixteen examples of the second-generation of HCV NS3/4A inhibitors, mainly focusing on the clinical application, structure development, structure-activity relationship (SAR) and their synthesis.
Export Options
About this article
Cite this article as:
Wang Shuni , Wang Yibing, Wang Jiang, Sato Tatsunori, Izawa Kunisuke *, Soloshonok A. Vadim*, Liu Hong*, The Second-generation of Highly Potent Hepatitis C Virus (HCV) NS3/4A Protease Inhibitors: Evolutionary Design Based on Tailor-made Amino Acids, Synthesis and Major Features of Bio-activity, Current Pharmaceutical Design 2017; 23 (30) . https://dx.doi.org/10.2174/1381612823666170522122424
DOI https://dx.doi.org/10.2174/1381612823666170522122424 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Ligands View of Target Similarity: Chemogenomic Binding Site- Directed Techniques for Drug Discovery
Current Topics in Medicinal Chemistry Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Molecular Insights on Bioactive Compounds against Covid-19: A Network Pharmacological and Computational Study
Current Computer-Aided Drug Design New Approaches for the Treatment of Allergic Conditions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cinnamaldehyde for the Treatment of Microbial Infections: Evidence Obtained from Experimental Models
Current Medicinal Chemistry Efficacy and Safety Study of Fixed-Dose Combination of Ceftriaxone- Vancomycin Injection in Patients with Various Infections
Current Drug Safety The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Small Molecule Aurora Kinases Inhibitors
Current Medicinal Chemistry Ionic Liquid Mediated Tandem Synthesis of Bioactive Quinoline Based Thiophene/ Thiazole Linked Multi-Heterocomponent Ugi Adducts
Current Organic Chemistry Testosterone Based Esters as Inhibitors of Aromatase (AR) and the use of the Substrate-Haem Complex Approach in the Rationalisation of the Inhibitory Activity of these Compounds
Letters in Drug Design & Discovery Anti-Infective Strategies of the Future: Is there Room for Species-Specific Antibacterial Agents?
Current Pharmaceutical Design Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Advances in Computational Methods to Discover New NS2B-NS3 Inhibitors Useful Against Dengue and Zika Viruses
Current Topics in Medicinal Chemistry Editorial
Pharmaceutical Nanotechnology Epidemiology and Pathophysiology of Chronic Cough
Current Respiratory Medicine Reviews Hepatocyte Growth Factor (HGF), an Endogenous Pulmotrophic Regulator, for the Rescue of Acute and Chronic Lung Diseases
Current Signal Transduction Therapy Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design Tele-Oncology: An Emerging Technology in Developing Countries during the COVID-19 Pandemic
New Emirates Medical Journal Annexins in the Central Nervous System: Are they Neuroprotective or Proapoptotic Agents?
Medicinal Chemistry Reviews - Online (Discontinued) Antifeedant Activity of Camptothecin and its Semisynthetic Derivatives Against Spodoptera litura (Fabricius) (Lepidoptera: Noctuidae) Larvae
Current Bioactive Compounds